The CARxALL clinical study is a First-in-Human, open-label, single-arm, dose-escalation clinical study designed to assess the safety and preliminary efficacy of OC-1, in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/R T-ALL).
Read More